Dr. Kelly and her colleagues synthesized a panel of PDCs aiming at the precise treatment of pulmonary fibrosis, where nintedanib – a potent kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis – and a peptidomimetic targeting αVβ6 integrin – which is a receptor overexpressed in fibrotic tissues – are connected by different linkers. Given the promising in vitro results of one synthesized PDC, the in vivo antifibrotic activity is currently under evaluation in mice models of pulmonary fibrosis.

Free registration at https://www.bocsci.com/holding-hands-using-peptide-drug-conjugates-pdcs-for-the-precise-treatment-of-pulmonary-fibrosis.html